{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:10:37Z","timestamp":1772521837242,"version":"3.50.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Upadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis. The current case report describes two UC patients with high thromboembolic risk successfully treated with upadacitinib and rivaroxaban. The two patients reported increased stool frequency, decreased stool consistency, abdominal pain and hematochezia, both of whom had experienced mesalazine, corticosteroids, vedolizumab and infliximab, all failed to induce clinical remission. The male patient had a history of deep vein thrombosis (DVT) in his left lower limb, and the female patient had thrombophlebitis in a branch of the cephalic vein on the left forearm. After multidisciplinary conference and thorough informed consent, upadacitinib and rivaroxaban were applied. Two months after the initiation of treatment, the patients\u2019 symptoms and endoscopic findings improved significantly. No thromboembolic events or other adverse effects have been observed to date. Our case report suggests that concurrent use of anticoagulation with upadacitinib may represent a safe and valuable strategy for treating refractory UC with high thromboembolic risk.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1716943","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:20Z","timestamp":1772520560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxia","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghua","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","unstructured":"Janus kinase (JAK) inhibitors: Drug Safety Communication - FDA requires warnings about increased risk of serious heart-related events, cancer, blood and death\n          \n          \n          \n          2021"},{"key":"B4","unstructured":"EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders\n          \n          \n          \n          2023"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1683751","article-title":"Post-marketing surveillance of upadacitinib: multilevel analysis of venous thromboembolism reporting in global data and rheumatoid arthritis","volume":"12","author":"Ferreira-da-Silva","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrgastro.2014.202","article-title":"Epidemiology, risk factors and management of cardiovascular diseases in IBD","volume":"12","author":"Singh","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three Janus kinase inhibitors in ulcerative colitis: A real-world multicentre study in Japan","volume":"61","author":"Lowell","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjsurg.2009.10.006","article-title":"Risk assessment as a guide for the prevention of the many faces of venous thromboembolism","volume":"199","author":"Caprini","year":"2010","journal-title":"Am J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae100","article-title":"Pharmacologic anticoagulation is associated with a lower risk of recurrent venous thromboembolic events during Janus kinase inhibitor use for patients with a prior thrombosis","volume":"31","author":"Lowell","year":"2025","journal-title":"Inflammation Bowel Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236894","article-title":"The effect of upadacitinib on lipid profile and cardiovascular events: A meta-analysis of randomized controlled trials","volume":"11","author":"Makris","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1716943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:30Z","timestamp":1772520570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1716943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2026.1716943"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1716943","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1716943"}}